Skip to main content
Erschienen in: European Surgery 5/2019

10.04.2019 | original article

Prognostic impact of allogenic blood transfusion following surgical treatment of esophageal cancer

verfasst von: Assistant Professor Dejan Velickovic, MD, Associate Professor Predrag Sabljak, MD, PhD, Associate Professor Dejan Stojakov, MD, PhD, Assistant Professor Jelena Velickovic, MD, Assistant Professor Keramatollah Ebrahimi, MD, PhD, Assistant Professor Vladimir Sljukic, MD, Professor Predrag Pesko, MD, PhD, FACS

Erschienen in: European Surgery | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Summary

Background

Esophageal cancer (EC) surgery is associated with relatively high morbidity and mortality rates and poor overall survival (OS). The impact of allogeneic blood transfusion (aBT) on OS is still a matter of debate. We aimed to investigate the impact of aBT on OS in a homogeneous population of patients undergoing surgical treatment for EC in a single center during a 15-year period.

Methods

In total, 409 patients who had undergone surgical resection for EC were studied. The clinicopathological parameters and OS were compared between 170 patients (41.6%) who received perioperative aBT and 239 patients (58.4%) who did not.

Results

Compared with the non-transfused patients, patients who received aBT had lower preoperative hemoglobin levels, more comorbidities, and a more advanced stage of disease as reflected by tumor diameter, nodal metastases, perineural invasion, and the need for multiorgan resection. Transfused patients suffered more frequently from major postoperative complications (26/170 [21.5%] vs. 13/239 [5.7%], p < 0.001) and had a significantly longer hospital stay (17 vs. 15 days, p < 0.001). Multivariate analysis identified tumor grade (p = 0.02), perineural invasion (p = 0.001), N stage (p < 0.001), major postoperative complications (p = 0.01), and comorbidity (p = 0.04) as independent predictors of OS in patients with EC. Perioperative aBT was not found to be an independent predictor of OS in the entire cohort, neither in the stratified subanalysis.

Conclusion

In our study, an advanced stage of disease and comorbidities resulted in the need for blood transfusion and the occurrence of major postoperative complications, which appeared to decrease the OS in patients with EC.
Literatur
1.
Zurück zum Zitat GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.CrossRef GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.CrossRef
2.
Zurück zum Zitat GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602.CrossRef GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602.CrossRef
3.
Zurück zum Zitat Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–9.CrossRefPubMedPubMedCentral Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–9.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Lepage C, Rachet B, Jooste V, et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–9.CrossRefPubMed Lepage C, Rachet B, Jooste V, et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008;103:2694–9.CrossRefPubMed
5.
Zurück zum Zitat Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.CrossRefPubMed Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008;122:1118–29.CrossRefPubMed
6.
Zurück zum Zitat Reeh M, Ghadban T, Dedow J, et al. Allogenic blood transfusion is associated with poor perioperative and long-term outcome in esophageal cancer. World J Surg. 2017;41:208–15.CrossRefPubMed Reeh M, Ghadban T, Dedow J, et al. Allogenic blood transfusion is associated with poor perioperative and long-term outcome in esophageal cancer. World J Surg. 2017;41:208–15.CrossRefPubMed
7.
Zurück zum Zitat Wouters MW, Krijnen P, Le Cessie S, et al. Volume or outcome-based referral to improve quality of care for esophageal cancer surgery in The Netherlands. J Surg Oncol. 2009;99:481–7.CrossRefPubMed Wouters MW, Krijnen P, Le Cessie S, et al. Volume or outcome-based referral to improve quality of care for esophageal cancer surgery in The Netherlands. J Surg Oncol. 2009;99:481–7.CrossRefPubMed
8.
Zurück zum Zitat Pennathur A, Luketich JD. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg. 2008;85:S751–S6.CrossRefPubMed Pennathur A, Luketich JD. Resection for esophageal cancer: strategies for optimal management. Ann Thorac Surg. 2008;85:S751–S6.CrossRefPubMed
9.
Zurück zum Zitat Boshier PR, Ziff C, Adam ME, et al. Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31:1–10. Boshier PR, Ziff C, Adam ME, et al. Effect of perioperative blood transfusion on the long-term survival of patients undergoing esophagectomy for esophageal cancer: a systematic review and meta-analysis. Dis Esophagus. 2018;31:1–10.
10.
Zurück zum Zitat Lee J, Chin JH, Kim JI, et al. Association between red blood cell transfusion and long-term mortality in patients with cancer of the esophagus after esophagectomy. Dis Esophagus. 2017;31:1–8. Lee J, Chin JH, Kim JI, et al. Association between red blood cell transfusion and long-term mortality in patients with cancer of the esophagus after esophagectomy. Dis Esophagus. 2017;31:1–8.
11.
Zurück zum Zitat Nozoe T, Miyazaki M, Saeki H, et al. Significance of allogenic blood transfusion on decreased survival in patients with esophageal carcinoma. Cancer. 2001;92:1913–8.CrossRefPubMed Nozoe T, Miyazaki M, Saeki H, et al. Significance of allogenic blood transfusion on decreased survival in patients with esophageal carcinoma. Cancer. 2001;92:1913–8.CrossRefPubMed
12.
Zurück zum Zitat Komatsu Y, Orita H, Sakurada M, et al. Intraoperative blood transfusion contributes to the decreased long-term survival of patients with esophageal cancer. World J Surg. 2012;36:844–50.CrossRefPubMed Komatsu Y, Orita H, Sakurada M, et al. Intraoperative blood transfusion contributes to the decreased long-term survival of patients with esophageal cancer. World J Surg. 2012;36:844–50.CrossRefPubMed
13.
Zurück zum Zitat Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48.CrossRefPubMed Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48.CrossRefPubMed
14.
Zurück zum Zitat Cata JP, Wang H, Gottumukkala V, et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth. 2013;110:690–701.CrossRefPubMedPubMedCentral Cata JP, Wang H, Gottumukkala V, et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth. 2013;110:690–701.CrossRefPubMedPubMedCentral
15.
16.
Zurück zum Zitat Liu J, Chen S, Chen Y, et al. Perioperative blood transfusion has no effect on overall survival after esophageal resection for esophageal squamous cell carcinoma: a retrospective cohort study. Int J Surg. 2018;55:24–30.CrossRefPubMed Liu J, Chen S, Chen Y, et al. Perioperative blood transfusion has no effect on overall survival after esophageal resection for esophageal squamous cell carcinoma: a retrospective cohort study. Int J Surg. 2018;55:24–30.CrossRefPubMed
17.
Zurück zum Zitat Fjederholt KT, Svendsen LB, Mortensen FV. Perioperative blood transfusions increases the risk of anastomotic leakage after surgery for GEJ-cancer. Am J Surg. 2017;214:293–8.CrossRef Fjederholt KT, Svendsen LB, Mortensen FV. Perioperative blood transfusions increases the risk of anastomotic leakage after surgery for GEJ-cancer. Am J Surg. 2017;214:293–8.CrossRef
18.
Zurück zum Zitat Meiser A, Casagranda O, Skipka G, et al. Quantification of blood loss. How precise is visual estimation and what does its accuracy depend on? Anaesthesist. 2001;50:13–20.CrossRefPubMed Meiser A, Casagranda O, Skipka G, et al. Quantification of blood loss. How precise is visual estimation and what does its accuracy depend on? Anaesthesist. 2001;50:13–20.CrossRefPubMed
19.
Zurück zum Zitat Ng T, Ryder BA, Chern H, et al. Leukocyte-depleted blood transfusion is associated with decreased survival in resected early-stage lung cancer. J Thorac Cardiovasc Surg. 2012;143:815–9.CrossRefPubMed Ng T, Ryder BA, Chern H, et al. Leukocyte-depleted blood transfusion is associated with decreased survival in resected early-stage lung cancer. J Thorac Cardiovasc Surg. 2012;143:815–9.CrossRefPubMed
20.
Zurück zum Zitat Squires MH 3rd, Kooby DA, Poultsides GA, et al. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7‑institution analysis of 765 patients from the US gastric cancer collaborative. J Am Coll Surg. 2015;221:767–77.CrossRefPubMed Squires MH 3rd, Kooby DA, Poultsides GA, et al. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7‑institution analysis of 765 patients from the US gastric cancer collaborative. J Am Coll Surg. 2015;221:767–77.CrossRefPubMed
21.
Zurück zum Zitat Mavros MN, Xu L, Maqsood H, et al. Perioperative blood transfusion and the prognosis of pancreatic cancer surgery: systematic review and meta-analysis. Ann Surg Oncol. 2015;22:4382–91.CrossRefPubMed Mavros MN, Xu L, Maqsood H, et al. Perioperative blood transfusion and the prognosis of pancreatic cancer surgery: systematic review and meta-analysis. Ann Surg Oncol. 2015;22:4382–91.CrossRefPubMed
22.
Zurück zum Zitat Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta analysis. Ann Surg. 2012;256:235–44.CrossRefPubMed Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta analysis. Ann Surg. 2012;256:235–44.CrossRefPubMed
23.
Zurück zum Zitat Sugita S, Sasaki A, Iwaki K, et al. Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol. 2008;34:339–45.CrossRefPubMed Sugita S, Sasaki A, Iwaki K, et al. Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol. 2008;34:339–45.CrossRefPubMed
24.
Zurück zum Zitat Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978;299:799–803.CrossRefPubMed Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978;299:799–803.CrossRefPubMed
25.
Zurück zum Zitat Lenhard V, Massen G, Seifert P, et al. Characterization of transfusion-induced suppressor cells in prospective kidney allograft recipients. Transplant Proc. 1982;14:329–32.PubMed Lenhard V, Massen G, Seifert P, et al. Characterization of transfusion-induced suppressor cells in prospective kidney allograft recipients. Transplant Proc. 1982;14:329–32.PubMed
26.
Zurück zum Zitat Kaplan J, Sarnaik S, Gitlin J, et al. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood. 1984;64:308–10.CrossRef Kaplan J, Sarnaik S, Gitlin J, et al. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood. 1984;64:308–10.CrossRef
27.
Zurück zum Zitat Wood ML, Gottschalk R, Monaco AP. Effect of blood transfusion on IL-2 production. Transplantation. 1988;45:930–5.CrossRefPubMed Wood ML, Gottschalk R, Monaco AP. Effect of blood transfusion on IL-2 production. Transplantation. 1988;45:930–5.CrossRefPubMed
28.
Zurück zum Zitat Marquet RL, Hoynck van Papendrecht MA, Busch OR, et al. Blood donation leads to a decrease in natural killer cell activity: a study in normal blood donors and cancer patients. Transfusion. 1992;33:368–73.CrossRef Marquet RL, Hoynck van Papendrecht MA, Busch OR, et al. Blood donation leads to a decrease in natural killer cell activity: a study in normal blood donors and cancer patients. Transfusion. 1992;33:368–73.CrossRef
29.
Zurück zum Zitat Fields RC, Meyers BF. The effects of perioperative blood transfusion on morbidity and mortality after esophagectomy. Thorac Surg Clin. 2006;16:75–86.CrossRefPubMed Fields RC, Meyers BF. The effects of perioperative blood transfusion on morbidity and mortality after esophagectomy. Thorac Surg Clin. 2006;16:75–86.CrossRefPubMed
30.
Zurück zum Zitat Swisher SG, Holmes EC, Hunt KK, et al. Perioperative blood transfusions and decreased long-term survival in esophageal cancer. J Thorac Cardiovasc Surg. 1996;112:341–8.CrossRefPubMed Swisher SG, Holmes EC, Hunt KK, et al. Perioperative blood transfusions and decreased long-term survival in esophageal cancer. J Thorac Cardiovasc Surg. 1996;112:341–8.CrossRefPubMed
31.
Zurück zum Zitat Tachibana M, Tabara H, Kotoh T, et al. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Am J Gastroenterol. 1999;94:757–65.CrossRefPubMed Tachibana M, Tabara H, Kotoh T, et al. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Am J Gastroenterol. 1999;94:757–65.CrossRefPubMed
32.
Zurück zum Zitat Craig SR, Adam DJ, Yap PL, et al. Effect of blood transfusion on survival after esophagogastrectomy for carcinoma. Ann Thorac Surg. 1998;66:356–61.CrossRefPubMed Craig SR, Adam DJ, Yap PL, et al. Effect of blood transfusion on survival after esophagogastrectomy for carcinoma. Ann Thorac Surg. 1998;66:356–61.CrossRefPubMed
33.
Zurück zum Zitat Dresner SM, Lamb PJ, Shenfine J, et al. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol. 2000;26:492–7.CrossRefPubMed Dresner SM, Lamb PJ, Shenfine J, et al. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol. 2000;26:492–7.CrossRefPubMed
34.
Zurück zum Zitat Langley SM, Alexiou C, Bailey DH, et al. The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma. Ann Thorac Surg. 2002;73:1704–9.CrossRefPubMed Langley SM, Alexiou C, Bailey DH, et al. The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma. Ann Thorac Surg. 2002;73:1704–9.CrossRefPubMed
35.
Zurück zum Zitat Nafteux P, Depypere L, Van Veer H, et al. Principles of esophageal cancer surgery, including surgical approaches and optimal node dissection (2- vs. 3‑field). Ann Cardiothorac Surg. 2017;6:152–8.CrossRefPubMedPubMedCentral Nafteux P, Depypere L, Van Veer H, et al. Principles of esophageal cancer surgery, including surgical approaches and optimal node dissection (2- vs. 3‑field). Ann Cardiothorac Surg. 2017;6:152–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostic impact of allogenic blood transfusion following surgical treatment of esophageal cancer
verfasst von
Assistant Professor Dejan Velickovic, MD
Associate Professor Predrag Sabljak, MD, PhD
Associate Professor Dejan Stojakov, MD, PhD
Assistant Professor Jelena Velickovic, MD
Assistant Professor Keramatollah Ebrahimi, MD, PhD
Assistant Professor Vladimir Sljukic, MD
Professor Predrag Pesko, MD, PhD, FACS
Publikationsdatum
10.04.2019
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 5/2019
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-019-0588-7

Weitere Artikel der Ausgabe 5/2019

European Surgery 5/2019 Zur Ausgabe